Effects of race and ethnicity on the incidence of venous thromboembolism

White, Richard; Keenan, Craig R

doi:10.1016/s0049-3848(09)70136-7

Cited by 348 publications

(263 citation statements)

References 29 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…However, androgen deprivation may cause atherosclerotic plaque progression and instability, 15 and its use has been associated with an increased risk of coronary heart disease. [16][17][18][19][20] Consistent with evidence that aging 21 and cancer 22 are associated with an increased risk of venous thromboembolism (i.e., pulmonary embolism and deep venous thrombosis), a population-based study of the Swedish National Prostate Cancer Register demonstrated that prostate cancer was associated with an increased risk of venous thromboembolism, and men with prostate cancer treated with androgen deprivation therapy were at greatest risk for venous thrmoboembolism. 23 We sought to corroborate the association of androgen deprivation therapy with venous thromboembolism among older Americans with prostate cancer.…”

Section: Introductionmentioning

confidence: 77%

170 Androgen Deprivation Therapy for Non-Metastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous Thromboembolism

Williams¹,

O’Malley

Smith

et al. 2012

Journal of Urology

View full text Add to dashboard Cite

Background-Previous studies demonstrate that androgen deprivation therapy with gonodotropin-releasing hormone (GnRH) agonists and orchiectomy for prostate cancer is associated with cardiovascular disease. However, few studies have examined its effect on the peripheral vascular system.Objective-To study the risk of peripheral arterial disease and venous thromboembolism associated with androgen deprivation therapy for prostate cancer.Design, Settings and Participants-Population-based observational study of 182,757 U.S. men aged 66 years and older who were diagnosed with loco-regional prostate cancer from 1992 to 2007, of whom 47.8% received GnRH agonists and 2.2% orchiectomy.Measurements-We used Cox proportional hazards models with time-varying treatment variables to assess whether treatment with GnRH agonists or orchiectomy was associated with peripheral arterial disease and/or venous thromboembolism.Results and limitations-Overall, 47.8% of men received a GnRH agonist during follow-up and 2.2% underwent orchiectomy. GnRH agonist use was associated with an increased risk of incident peripheral arterial disease (adjusted hazard ratio [HR], 1.15, 95% confidence interval [CI] 1.11-1.19) and incident venous thromboembolism (adjusted HR, 1.1, 95% CI 1.04-1.16). In addition, orchiectomy was associated with an increased risk of peripheral arterial disease (adjusted HR, 1.14, 95% CI 1.03-1.27) and venous thromboembolism (adjusted HR, 1.22, 95% CI 1.07-1.40). Limitations include the observational study design, inability to assess the use of oral antiandrogens as monotherapy or combined androgen deprivation.Conclusions-Androgen deprivation therapy for loco-regional prostate cancer is associated with an increased risk of peripheral artery disease and venous thromboembolism. Additional research is needed to better understand the potential risks and benefits, so that these treatments can be targeted to patients where the benefits are most clear.

show abstract

Section: Introductionmentioning

confidence: 77%

170 Androgen Deprivation Therapy for Non-Metastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous Thromboembolism

Williams¹,

O’Malley

Smith

et al. 2012

Journal of Urology

View full text Add to dashboard Cite

show abstract

“…However, in recent years, many studies have been done among a small number of ethnic groups 26, 27, 28, 29, 30, 31, 32, 33, 34. In general, Asians and Native Americans tended to have the lowest incidence of VTE,26, 35, 36, 37, 38, 39 whereas several studies mainly conducted in the United States have shown a higher VTE incidence in Blacks 39, 40, 41. In this study we found a similar IR among immigrants from predominantly Black countries compared to White immigrants.…”

Section: Discussionmentioning

confidence: 99%

Immigration, region of origin, and the epidemiology of venous thromboembolism: A population‐based study

Lazo‐Langner

Liu

Shariff

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

BackgroundVenous thromboembolism (VTE) epidemiology has been mainly studied in populations largely of European ancestry.ObjectivesTo assess the epidemiology of VTE in immigrants to Ontario, Canada.Patients/MethodsWe conducted a population‐based retrospective cohort study using linked health‐care and administrative databases. We included 1 195 791 immigrants to Ontario and 1 195 791 nonimmigrants, matched on age, sex, and place of residence. The main exposure was ethnicity according to world region of origin, using a previously validated algorithm. The main outcome was incident onset of VTE during the period of observation. Risk ratios (RR) were calculated using Poisson regression models.ResultsThe incidence rate (IR) of VTE was lower among immigrants (0.87 per 1000 PY; 95% confidence interval [CI] 0.85‐0.89) than nonimmigrants (1.59 per 1000 PY; 95% CI 1.56‐1.61). Age‐ and sex‐standardized IR were lower among East and South Asian immigrants. Compared to immigrants for predominantly White regions, age‐ and sex‐specific RRs were consistently lower for East Asian (0.18‐0.30) and South Asian (0.29‐0.75) immigrants. In contrast, the RRs of VTE among Black (0.38‐1.50), Latin American (0.29‐1.25), Arab/Middle Eastern (0.44‐1.08) and West Asian (0.31‐1.16) immigrants were not significantly different from White immigrants.ConclusionsIn Ontario, the incidence of VTE is lower among immigrants compared to nonimmigrants. East and South Asian immigrants have a lower risk of VTE compared to White immigrants.

show abstract

“…According to this defi nition several studies record a nearly 40-50% of unprovoked VTE in real life [5] and according to common thrombotic risk factors suggested by guidelines 2014; yet other clinical conditions are well known as conditions that may predispose for VTE as infl ammatory bowel disease, immunopathological disease and/or connectivitis, nephritic syndrome and others [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

“…Around 40% of VTE patients have unprovoked VTE in real life [2][3][4]. In clinical practice around 40-50% of VTE cases are classifi ed as unprovoked VTE in most clinical trials and \ or registries [4][5][6]. For this reason.…”

Section: Introductionmentioning

confidence: 99%

Should We Screen Patients with Unprovoked Venous Thromboembolism for Hyperthyroidism? Report of Several Paradigmatic Clinical Cases from the RIETE Registry

Micco¹,

Gussoni²,

Uresandi³

et al. 2017

Arch Hematol Case Rep Rev

View full text Add to dashboard Cite

Unprovoked venous thromboembolism (VTE) is defi ned as a VTE appearing in the absence of the common risk factors including cancer, surgery, hypomobility, oestrogen use or pregnancy. Around 40% of VTE patients have unprovoked VTE in real life. However, a number of additional clinical conditions may be associated to ahypercoagulable state and induce VTE, though they are less often considered in clinical practice such as the abnormalities of the thyroid function. Here we report three relevant casereports that we found in the RIETE registry in which overt hyperthyroidism is the only apparent cause of haemodynamic unstable acute pulmonary embolism (PE).

show abstract

Effects of race and ethnicity on the incidence of venous thromboembolism

Cited by 348 publications

References 29 publications

170 Androgen Deprivation Therapy for Non-Metastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous Thromboembolism

170 Androgen Deprivation Therapy for Non-Metastatic Prostate Cancer Is Associated With an Increased Risk of Peripheral Arterial Disease and Venous Thromboembolism

Immigration, region of origin, and the epidemiology of venous thromboembolism: A population‐based study

Should We Screen Patients with Unprovoked Venous Thromboembolism for Hyperthyroidism? Report of Several Paradigmatic Clinical Cases from the RIETE Registry

Contact Info

Product

Resources

About